<DOC>
	<DOCNO>NCT02536313</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability treatment sofosbuvir/velpatasvir/voxilaprevir ( SOF/VEL/VOX ) fix dose combination ( FDC ) Â± ribavirin ( RBV ) participants chronic genotype 1 hepatitis C virus ( HCV ) infection prior treatment experience direct act antiviral measure proportion participant sustain viral response 12 week cessation treatment ( SVR12 ) .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With Without Ribavirin Participants With Chronic Genotype 1 HCV Infection Previously Treated With Direct Acting Antiviral Regimen</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Individuals chronic HCV genotype 1 infection Documented treatment experience direct act antiviralcontaining regimen without achieve sustained viral response Absence cirrhosis presence compensate cirrhosis Screening laboratory value within defined threshold Must use specific contraceptive method female childbearing potential sexually active male Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>